Australia's Rx drug bill to rise 600% in 40 years

8 April 2007

Despite reducing its estimate of prescription drug cost rises, Australia's Treasury has forecast that, by 2046, government spending on drugs will rise six-fold to reach A$2,200 per person each year. The revised figure is about 25% lower than the government department's initial calculation, but includes the impact of greater generic drug prescribing.

The findings come in Australia's latest intergenerational report, which also examines the impact of demographic changes on other welfare programs, including health care, child benefits and unemployment payments.

Treasurer Peter Costello has ruled out drastic changes to the health care funding system, according to the Brisbane Times, even though government spending on health care is expected to rise at 4.4% annually, or nearly three times the entire economy's growth rate when adjusted for inflation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight